Loading…
E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders
A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identificati...
Saved in:
| Published in: | European journal of paediatric neurology 2020-11, Vol.29, p.22-31 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3 |
| container_end_page | 31 |
| container_issue | |
| container_start_page | 22 |
| container_title | European journal of paediatric neurology |
| container_volume | 29 |
| creator | Armangue, Thaís Capobianco, Marco de Chalus, Aliénor Laetitia, Giorgi Deiva, Kumaran Bruijstens, Arlette L. Wendel, Eva-Maria Lechner, Christian Bartels, Frederik Finke, Carsten Breu, Markus Flet-Berliac, Lorraine Adamsbaum, Catherine Hacohen, Yael Hemingway, Cheryl Wassmer, Evangeline Lim, Ming Baumann, Matthias Wickström, Ronny Rostasy, Kevin Neuteboom, Rinze F. |
| description | A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
•Cell based assays with serum are the test of choice for MOG antibody testing.•Serial testing of MOG antibodies can give information about risk of relapses.•Recent data from animal models suggest that MOG antibodies are pathogenic.•OCB have a high positive predictive value for the diagnosis of MS but not MOGAD.•New biomarkers may help to monitor disease activity in MOGAD in the future. |
| doi_str_mv | 10.1016/j.ejpn.2020.11.001 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2461003744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1090379820302051</els_id><sourcerecordid>2461003744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3</originalsourceid><addsrcrecordid>eNp9Uctu1TAQtSqqvuAHukBeskkY24lvgthAVQpSq3ZB15ZjTyrfJvHFdpCy4w9Y8Id8SX25bcWqK48855yZM4eQUwYlAybfr0tcb6aSA88frARge-SI1YIXnAl4lWtooRCrtjkkxzGuAaCtuDwgh0KwNjflEfl9Xt6WdKPROp2CM_Tq-oIaP0UfkpvHfyVOcY4f6I0OiQr699cf-tn5UYd7DJH6_n_2uODgJuoHd-ctTjZ4sySkd8Ni_Cb4hLmpp-Q6b5dCx-hNJqKl1uWBNuu9Jvu9HiK-eXxPyO2X8-9nX4vL64tvZ58uC1OJJhUN9F0PEqDnDIQRlRS2a6BrZV21clVnnzUy7Fat1B1wWTOokYum5kzWokVxQt7tdPNWP2aMSY0uGhwGPaGfo-KVZABiVVUZyndQE3yMAXu1CS7bXxQDtQ1CrdU2CLUNQjGmchCZ9PZRf-5GtM-Up8tnwMcdALPLnw6DisbhZPIpA5qkrHcv6T8ATeubcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461003744</pqid></control><display><type>article</type><title>E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders</title><source>Elsevier</source><creator>Armangue, Thaís ; Capobianco, Marco ; de Chalus, Aliénor ; Laetitia, Giorgi ; Deiva, Kumaran ; Bruijstens, Arlette L. ; Wendel, Eva-Maria ; Lechner, Christian ; Bartels, Frederik ; Finke, Carsten ; Breu, Markus ; Flet-Berliac, Lorraine ; Adamsbaum, Catherine ; Hacohen, Yael ; Hemingway, Cheryl ; Wassmer, Evangeline ; Lim, Ming ; Baumann, Matthias ; Wickström, Ronny ; Rostasy, Kevin ; Neuteboom, Rinze F.</creator><creatorcontrib>Armangue, Thaís ; Capobianco, Marco ; de Chalus, Aliénor ; Laetitia, Giorgi ; Deiva, Kumaran ; Bruijstens, Arlette L. ; Wendel, Eva-Maria ; Lechner, Christian ; Bartels, Frederik ; Finke, Carsten ; Breu, Markus ; Flet-Berliac, Lorraine ; Adamsbaum, Catherine ; Hacohen, Yael ; Hemingway, Cheryl ; Wassmer, Evangeline ; Lim, Ming ; Baumann, Matthias ; Wickström, Ronny ; Rostasy, Kevin ; Neuteboom, Rinze F. ; E.U. paediatric MOG consortium</creatorcontrib><description>A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
•Cell based assays with serum are the test of choice for MOG antibody testing.•Serial testing of MOG antibodies can give information about risk of relapses.•Recent data from animal models suggest that MOG antibodies are pathogenic.•OCB have a high positive predictive value for the diagnosis of MS but not MOGAD.•New biomarkers may help to monitor disease activity in MOGAD in the future.</description><identifier>ISSN: 1090-3798</identifier><identifier>EISSN: 1532-2130</identifier><identifier>DOI: 10.1016/j.ejpn.2020.11.001</identifier><identifier>PMID: 33191096</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Acquired demyelinating syndromes ; Autoantibodies - blood ; Autoantibodies - immunology ; Autoantigens - immunology ; Biomarkers ; Biomarkers - analysis ; Cell based assays ; Child ; Children ; Demyelinating Autoimmune Diseases, CNS - diagnosis ; Demyelinating Autoimmune Diseases, CNS - immunology ; Humans ; Myelin-oligodendrocyte glycoprotein ; Myelin-Oligodendrocyte Glycoprotein - immunology ; Neurofilament</subject><ispartof>European journal of paediatric neurology, 2020-11, Vol.29, p.22-31</ispartof><rights>2020 European Paediatric Neurology Society</rights><rights>Copyright © 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3</citedby><cites>FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3</cites><orcidid>0000-0001-6192-6171</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33191096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armangue, Thaís</creatorcontrib><creatorcontrib>Capobianco, Marco</creatorcontrib><creatorcontrib>de Chalus, Aliénor</creatorcontrib><creatorcontrib>Laetitia, Giorgi</creatorcontrib><creatorcontrib>Deiva, Kumaran</creatorcontrib><creatorcontrib>Bruijstens, Arlette L.</creatorcontrib><creatorcontrib>Wendel, Eva-Maria</creatorcontrib><creatorcontrib>Lechner, Christian</creatorcontrib><creatorcontrib>Bartels, Frederik</creatorcontrib><creatorcontrib>Finke, Carsten</creatorcontrib><creatorcontrib>Breu, Markus</creatorcontrib><creatorcontrib>Flet-Berliac, Lorraine</creatorcontrib><creatorcontrib>Adamsbaum, Catherine</creatorcontrib><creatorcontrib>Hacohen, Yael</creatorcontrib><creatorcontrib>Hemingway, Cheryl</creatorcontrib><creatorcontrib>Wassmer, Evangeline</creatorcontrib><creatorcontrib>Lim, Ming</creatorcontrib><creatorcontrib>Baumann, Matthias</creatorcontrib><creatorcontrib>Wickström, Ronny</creatorcontrib><creatorcontrib>Rostasy, Kevin</creatorcontrib><creatorcontrib>Neuteboom, Rinze F.</creatorcontrib><creatorcontrib>E.U. paediatric MOG consortium</creatorcontrib><title>E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders</title><title>European journal of paediatric neurology</title><addtitle>Eur J Paediatr Neurol</addtitle><description>A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
•Cell based assays with serum are the test of choice for MOG antibody testing.•Serial testing of MOG antibodies can give information about risk of relapses.•Recent data from animal models suggest that MOG antibodies are pathogenic.•OCB have a high positive predictive value for the diagnosis of MS but not MOGAD.•New biomarkers may help to monitor disease activity in MOGAD in the future.</description><subject>Acquired demyelinating syndromes</subject><subject>Autoantibodies - blood</subject><subject>Autoantibodies - immunology</subject><subject>Autoantigens - immunology</subject><subject>Biomarkers</subject><subject>Biomarkers - analysis</subject><subject>Cell based assays</subject><subject>Child</subject><subject>Children</subject><subject>Demyelinating Autoimmune Diseases, CNS - diagnosis</subject><subject>Demyelinating Autoimmune Diseases, CNS - immunology</subject><subject>Humans</subject><subject>Myelin-oligodendrocyte glycoprotein</subject><subject>Myelin-Oligodendrocyte Glycoprotein - immunology</subject><subject>Neurofilament</subject><issn>1090-3798</issn><issn>1532-2130</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9Uctu1TAQtSqqvuAHukBeskkY24lvgthAVQpSq3ZB15ZjTyrfJvHFdpCy4w9Y8Id8SX25bcWqK48855yZM4eQUwYlAybfr0tcb6aSA88frARge-SI1YIXnAl4lWtooRCrtjkkxzGuAaCtuDwgh0KwNjflEfl9Xt6WdKPROp2CM_Tq-oIaP0UfkpvHfyVOcY4f6I0OiQr699cf-tn5UYd7DJH6_n_2uODgJuoHd-ctTjZ4sySkd8Ni_Cb4hLmpp-Q6b5dCx-hNJqKl1uWBNuu9Jvu9HiK-eXxPyO2X8-9nX4vL64tvZ58uC1OJJhUN9F0PEqDnDIQRlRS2a6BrZV21clVnnzUy7Fat1B1wWTOokYum5kzWokVxQt7tdPNWP2aMSY0uGhwGPaGfo-KVZABiVVUZyndQE3yMAXu1CS7bXxQDtQ1CrdU2CLUNQjGmchCZ9PZRf-5GtM-Up8tnwMcdALPLnw6DisbhZPIpA5qkrHcv6T8ATeubcw</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Armangue, Thaís</creator><creator>Capobianco, Marco</creator><creator>de Chalus, Aliénor</creator><creator>Laetitia, Giorgi</creator><creator>Deiva, Kumaran</creator><creator>Bruijstens, Arlette L.</creator><creator>Wendel, Eva-Maria</creator><creator>Lechner, Christian</creator><creator>Bartels, Frederik</creator><creator>Finke, Carsten</creator><creator>Breu, Markus</creator><creator>Flet-Berliac, Lorraine</creator><creator>Adamsbaum, Catherine</creator><creator>Hacohen, Yael</creator><creator>Hemingway, Cheryl</creator><creator>Wassmer, Evangeline</creator><creator>Lim, Ming</creator><creator>Baumann, Matthias</creator><creator>Wickström, Ronny</creator><creator>Rostasy, Kevin</creator><creator>Neuteboom, Rinze F.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6192-6171</orcidid></search><sort><creationdate>20201101</creationdate><title>E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders</title><author>Armangue, Thaís ; Capobianco, Marco ; de Chalus, Aliénor ; Laetitia, Giorgi ; Deiva, Kumaran ; Bruijstens, Arlette L. ; Wendel, Eva-Maria ; Lechner, Christian ; Bartels, Frederik ; Finke, Carsten ; Breu, Markus ; Flet-Berliac, Lorraine ; Adamsbaum, Catherine ; Hacohen, Yael ; Hemingway, Cheryl ; Wassmer, Evangeline ; Lim, Ming ; Baumann, Matthias ; Wickström, Ronny ; Rostasy, Kevin ; Neuteboom, Rinze F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acquired demyelinating syndromes</topic><topic>Autoantibodies - blood</topic><topic>Autoantibodies - immunology</topic><topic>Autoantigens - immunology</topic><topic>Biomarkers</topic><topic>Biomarkers - analysis</topic><topic>Cell based assays</topic><topic>Child</topic><topic>Children</topic><topic>Demyelinating Autoimmune Diseases, CNS - diagnosis</topic><topic>Demyelinating Autoimmune Diseases, CNS - immunology</topic><topic>Humans</topic><topic>Myelin-oligodendrocyte glycoprotein</topic><topic>Myelin-Oligodendrocyte Glycoprotein - immunology</topic><topic>Neurofilament</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armangue, Thaís</creatorcontrib><creatorcontrib>Capobianco, Marco</creatorcontrib><creatorcontrib>de Chalus, Aliénor</creatorcontrib><creatorcontrib>Laetitia, Giorgi</creatorcontrib><creatorcontrib>Deiva, Kumaran</creatorcontrib><creatorcontrib>Bruijstens, Arlette L.</creatorcontrib><creatorcontrib>Wendel, Eva-Maria</creatorcontrib><creatorcontrib>Lechner, Christian</creatorcontrib><creatorcontrib>Bartels, Frederik</creatorcontrib><creatorcontrib>Finke, Carsten</creatorcontrib><creatorcontrib>Breu, Markus</creatorcontrib><creatorcontrib>Flet-Berliac, Lorraine</creatorcontrib><creatorcontrib>Adamsbaum, Catherine</creatorcontrib><creatorcontrib>Hacohen, Yael</creatorcontrib><creatorcontrib>Hemingway, Cheryl</creatorcontrib><creatorcontrib>Wassmer, Evangeline</creatorcontrib><creatorcontrib>Lim, Ming</creatorcontrib><creatorcontrib>Baumann, Matthias</creatorcontrib><creatorcontrib>Wickström, Ronny</creatorcontrib><creatorcontrib>Rostasy, Kevin</creatorcontrib><creatorcontrib>Neuteboom, Rinze F.</creatorcontrib><creatorcontrib>E.U. paediatric MOG consortium</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of paediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armangue, Thaís</au><au>Capobianco, Marco</au><au>de Chalus, Aliénor</au><au>Laetitia, Giorgi</au><au>Deiva, Kumaran</au><au>Bruijstens, Arlette L.</au><au>Wendel, Eva-Maria</au><au>Lechner, Christian</au><au>Bartels, Frederik</au><au>Finke, Carsten</au><au>Breu, Markus</au><au>Flet-Berliac, Lorraine</au><au>Adamsbaum, Catherine</au><au>Hacohen, Yael</au><au>Hemingway, Cheryl</au><au>Wassmer, Evangeline</au><au>Lim, Ming</au><au>Baumann, Matthias</au><au>Wickström, Ronny</au><au>Rostasy, Kevin</au><au>Neuteboom, Rinze F.</au><aucorp>E.U. paediatric MOG consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders</atitle><jtitle>European journal of paediatric neurology</jtitle><addtitle>Eur J Paediatr Neurol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>29</volume><spage>22</spage><epage>31</epage><pages>22-31</pages><issn>1090-3798</issn><eissn>1532-2130</eissn><abstract>A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD).
•Cell based assays with serum are the test of choice for MOG antibody testing.•Serial testing of MOG antibodies can give information about risk of relapses.•Recent data from animal models suggest that MOG antibodies are pathogenic.•OCB have a high positive predictive value for the diagnosis of MS but not MOGAD.•New biomarkers may help to monitor disease activity in MOGAD in the future.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33191096</pmid><doi>10.1016/j.ejpn.2020.11.001</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6192-6171</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1090-3798 |
| ispartof | European journal of paediatric neurology, 2020-11, Vol.29, p.22-31 |
| issn | 1090-3798 1532-2130 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2461003744 |
| source | Elsevier |
| subjects | Acquired demyelinating syndromes Autoantibodies - blood Autoantibodies - immunology Autoantigens - immunology Biomarkers Biomarkers - analysis Cell based assays Child Children Demyelinating Autoimmune Diseases, CNS - diagnosis Demyelinating Autoimmune Diseases, CNS - immunology Humans Myelin-oligodendrocyte glycoprotein Myelin-Oligodendrocyte Glycoprotein - immunology Neurofilament |
| title | E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A15%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=E.U.%20paediatric%20MOG%20consortium%20consensus:%20Part%203%20%E2%80%93%20Biomarkers%20of%20paediatric%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disorders&rft.jtitle=European%20journal%20of%20paediatric%20neurology&rft.au=Armangue,%20Tha%C3%ADs&rft.aucorp=E.U.%20paediatric%20MOG%20consortium&rft.date=2020-11-01&rft.volume=29&rft.spage=22&rft.epage=31&rft.pages=22-31&rft.issn=1090-3798&rft.eissn=1532-2130&rft_id=info:doi/10.1016/j.ejpn.2020.11.001&rft_dat=%3Cproquest_cross%3E2461003744%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-80fbf0600f2103c3463db80b965496759425e1eb796ab0265105e2385216539e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2461003744&rft_id=info:pmid/33191096&rfr_iscdi=true |